Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer.

ABSTRACT:

SUBMITTER: Borcoman E 

PROVIDER: S-EPMC7791256 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature